Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444534 | 1.00 | KDM4C (0.38) | KDM4CKDM6B | |
| SCHEMBL5131179 | 0.88 | KDM4C (0.41) | KDM4CKDM6B | |
| SCHEMBL2851860 | 0.88 | KDM4C (0.41) | KDM4CKDM6B | |
| SCHEMBL4451520 | 0.88 | KDM4C (0.41) | KDM4CKDM6B | |
| SCHEMBL4440148 | 0.85 | KDM4C (0.37) | KDM4C | |
| SCHEMBL4452197 | 0.85 | KDM4C (0.37) | KDM4C | |
| SCHEMBL5956871 | 0.82 | MAPT (0.44) | KDM4CKDM6B | |
| SCHEMBL4442650 | 0.82 | MAPT (0.44) | KDM4CKDM6B | |
| SCHEMBL2851538 | 0.82 | MAPT (0.44) | KDM4CKDM6B | |
| SCHEMBL5956745 | 0.80 | KDM4D (0.35) | KDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | claimed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | claimed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | claimed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | claimed |
| US-7696194-B2 | treating with fasudil hydrochloride; enzyme inhibitor of Rho kinase; promoting regeneration of an optic nerve cell | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| US-7109208-B2 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060148852-A1 | Visual function disorder improving agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20040106646-A1 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1378247-A1 | VISUAL FUNCTION IMPROVING AGENTS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | KDM4C 2667/4885KDM6B 2106/4885 |
| US-20040106646-A1 | Visual function disorder improving agents | ARHGDIA, GAP43, RHOT2 | KDM4C 3074/4885KDM6B 3262/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | KDM4C 4699/4885KDM6B 4043/4885 |
| US-20060148852-A1 | Visual function disorder improving agents | GAP43, ARHGDIA, RHOT2 | KDM4C 3275/4885KDM6B 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.